In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT).
[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer / Pasqualetti, F., Panichi, M., Sollini, M., Sainato, A., Galli, L., Morganti, R., Chiacchio, S., Marciano, A., Zanca, R., Mannelli, L., Coraggio, G., Sbrana, A., Cocuzza, P., Montrone, S., Baldaccini, D., Gonnelli, A., Molinari, A., Cantarella, M., Mazzotti, V., Ricci, S., et al.. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - 47:1(2020), pp. 185-191. [10.1007/s00259-019-04482-6]
[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer
Sollini, Martina;
2020-01-01
Abstract
In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT).| File | Dimensione | Formato | |
|---|---|---|---|
|
s00259-019-04482-6.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
371.37 kB
Formato
Adobe PDF
|
371.37 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
